HK Stock MarketDetailed Quotes

01875 TOT BIOPHARM-B

Watchlist
  • 2.040
  • +0.170+9.09%
Market Closed Jul 12 16:08 CST
1.58BMarket Cap-102000P/E (TTM)

TOT BIOPHARM-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
(FY)Dec 31, 2021
Turnover
67.79%222.54M
76.54%780.63M
77.25%541.98M
80.24%328.06M
65.28%132.63M
479.34%442.18M
744.11%305.78M
686.87%182.02M
450.25%80.25M
239.36%76.33M
Operating income
76.54%780.63M
80.24%328.06M
479.34%442.18M
686.87%182.02M
239.36%76.33M
Cost of sales
----
-188.76%-206.64M
----
-232.48%-78.06M
----
-46.49%-71.56M
----
-156.79%-23.48M
----
-601.78%-48.85M
Operating expenses
-188.76%-206.64M
-232.48%-78.06M
-46.49%-71.56M
-156.79%-23.48M
-601.78%-48.85M
Gross profit
54.87%573.99M
57.69%250M
1,248.97%370.62M
1,033.33%158.54M
76.91%27.47M
Selling expenses
----
-116.23%-441.02M
----
-181.60%-197.38M
----
-792.62%-203.95M
----
-525.70%-70.09M
----
11.96%-22.85M
Administrative expenses
----
-9.14%-68.31M
----
-21.04%-31.1M
----
-11.10%-62.59M
----
4.19%-25.7M
----
-20.23%-56.34M
Research and development expenses
----
31.28%-103.89M
----
28.89%-49.97M
----
29.59%-151.17M
----
20.82%-70.27M
----
8.71%-214.7M
Impairment and provision
----
-1,823.12%-11.48M
----
152.00%480K
----
---597K
----
---923K
----
----
-Other impairment is provision
----
-1,823.12%-11.48M
----
152.00%480K
----
---597K
----
---923K
----
----
Special items of operating profit
----
104.92%17.65M
----
798.05%13.39M
----
28.39%8.62M
----
156.05%1.49M
----
76.49%6.71M
Operating profit
15.40%-33.06M
-109.79%-14.58M
84.95%-39.08M
93.98%-6.95M
10.04%-259.7M
Financing income
----
31.30%2.97M
----
207.95%1.28M
----
133.75%2.27M
----
-41.88%415K
----
-48.46%969K
Financing cost
----
21.61%-5.18M
----
33.85%-2.26M
----
-167.50%-6.6M
----
-1,147.45%-3.42M
----
-44.67%-2.47M
Share of profit from joint venture company
----
62.39%-2.5M
----
106.88%397K
----
-38,917.65%-6.63M
----
---5.77M
----
---17K
Earning before tax
24.56%-37.76M
3.57%-15.16M
80.84%-50.05M
86.33%-15.72M
9.46%-261.22M
Tax
----
---1K
----
---1K
----
----
----
----
----
----
After-tax profit from continuing operations
24.56%-37.76M
3.57%-15.16M
80.84%-50.05M
86.33%-15.72M
9.46%-261.22M
Earning after tax
145.24%7.41M
24.56%-37.76M
22.28%-32.39M
3.57%-15.16M
-247.46%-16.38M
80.84%-50.05M
76.57%-41.68M
86.33%-15.72M
88.97%-4.71M
9.46%-261.22M
Minority profit
----
----
----
----
----
---130K
----
----
----
----
Profit attributable to shareholders
145.24%7.41M
24.36%-37.76M
20.10%-32.39M
3.57%-15.16M
-247.46%-16.38M
80.89%-49.92M
77.21%-40.54M
86.33%-15.72M
-4.71M
9.46%-261.22M
Basic earnings per share
37.50%-0.05
33.33%-0.02
82.61%-0.08
85.00%-0.03
9.80%-0.46
Diluted earnings per share
37.50%-0.05
33.33%-0.02
82.61%-0.08
85.00%-0.03
9.80%-0.46
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
Auditor
--
PricewaterhouseCoopers
--
--
--
PricewaterhouseCoopers
--
--
--
PricewaterhouseCoopers
(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022(FY)Dec 31, 2021
Turnover 67.79%222.54M76.54%780.63M77.25%541.98M80.24%328.06M65.28%132.63M479.34%442.18M744.11%305.78M686.87%182.02M450.25%80.25M239.36%76.33M
Operating income 76.54%780.63M80.24%328.06M479.34%442.18M686.87%182.02M239.36%76.33M
Cost of sales -----188.76%-206.64M-----232.48%-78.06M-----46.49%-71.56M-----156.79%-23.48M-----601.78%-48.85M
Operating expenses -188.76%-206.64M-232.48%-78.06M-46.49%-71.56M-156.79%-23.48M-601.78%-48.85M
Gross profit 54.87%573.99M57.69%250M1,248.97%370.62M1,033.33%158.54M76.91%27.47M
Selling expenses -----116.23%-441.02M-----181.60%-197.38M-----792.62%-203.95M-----525.70%-70.09M----11.96%-22.85M
Administrative expenses -----9.14%-68.31M-----21.04%-31.1M-----11.10%-62.59M----4.19%-25.7M-----20.23%-56.34M
Research and development expenses ----31.28%-103.89M----28.89%-49.97M----29.59%-151.17M----20.82%-70.27M----8.71%-214.7M
Impairment and provision -----1,823.12%-11.48M----152.00%480K-------597K-------923K--------
-Other impairment is provision -----1,823.12%-11.48M----152.00%480K-------597K-------923K--------
Special items of operating profit ----104.92%17.65M----798.05%13.39M----28.39%8.62M----156.05%1.49M----76.49%6.71M
Operating profit 15.40%-33.06M-109.79%-14.58M84.95%-39.08M93.98%-6.95M10.04%-259.7M
Financing income ----31.30%2.97M----207.95%1.28M----133.75%2.27M-----41.88%415K-----48.46%969K
Financing cost ----21.61%-5.18M----33.85%-2.26M-----167.50%-6.6M-----1,147.45%-3.42M-----44.67%-2.47M
Share of profit from joint venture company ----62.39%-2.5M----106.88%397K-----38,917.65%-6.63M-------5.77M-------17K
Earning before tax 24.56%-37.76M3.57%-15.16M80.84%-50.05M86.33%-15.72M9.46%-261.22M
Tax -------1K-------1K------------------------
After-tax profit from continuing operations 24.56%-37.76M3.57%-15.16M80.84%-50.05M86.33%-15.72M9.46%-261.22M
Earning after tax 145.24%7.41M24.56%-37.76M22.28%-32.39M3.57%-15.16M-247.46%-16.38M80.84%-50.05M76.57%-41.68M86.33%-15.72M88.97%-4.71M9.46%-261.22M
Minority profit -----------------------130K----------------
Profit attributable to shareholders 145.24%7.41M24.36%-37.76M20.10%-32.39M3.57%-15.16M-247.46%-16.38M80.89%-49.92M77.21%-40.54M86.33%-15.72M-4.71M9.46%-261.22M
Basic earnings per share 37.50%-0.0533.33%-0.0282.61%-0.0885.00%-0.039.80%-0.46
Diluted earnings per share 37.50%-0.0533.33%-0.0282.61%-0.0885.00%-0.039.80%-0.46
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions --Unqualified Opinion------Unqualified Opinion------Unqualified Opinion
Auditor --PricewaterhouseCoopers------PricewaterhouseCoopers------PricewaterhouseCoopers

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg